In order to continually and effectively compete with its peers, as well as with smaller specialty pharmaceutical companies and biotechnology companies, the top 20 global pharmaceutical peer set turns to deal-making as a means to balance out its internally developed portfolio, and to take advantage of the broader capabilities of partners or takeover targets. Through both alliances and therapeutically driven bolt-on acquisitions, the top 20 companies have in-licensed, co-developed, and acquired important assets to help advance their strategies.

This Datamonitor Healthcare report contains a Strategy module.